Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT07612176 is registered in ClinicalTrials.gov with NEOK Bio, Inc. as lead sponsor.

NCT NCT07612176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Lead sponsor
NEOK Bio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 21, 2026
Completion date
January 31, 2029
Enrollment
155 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced (unresectable) or metastatic solid tumors